Melanoma Unit, Mater Misericordiae Hospital
Newcastle, New South Wales, 2298, Australia
NCT Number: NCT00235482
The purpose of this study is to determine the safety of an injection of coxsackievirus A21 into a melanoma tumour, and also to see if there is a tumour response.
Looking for future studies?
Notify Me21 year–70 year
All sexes
Interventional
Phase 1
Newcastle, New South Wales, 2298, Australia
Coxsackievirus A21, a naturally occurring enterovirus, has shown that in vivo it can infect and lyse melanoma. This study is to assess safety of a single intratumoural injection of the virus into an accessible subcutaneous melanoma metastasis.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Viralytics
Industry
Acronym: PXS-X02
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01024231
Malignant Melanoma, Melanoma
New Haven, Connecticut, United States
View Trial DetailsNCT03236935
Bronchial Neoplasms, Carcinoma
Houston, Texas, United States
View Trial DetailsNCT07427953
Drug-Induced Retinopathy, Malignant Melanoma
Ljubljana, Slovenia
View Trial DetailsNCT07436390
Malignant Melanoma, Melanoma
Ljubljana, Slovenia
View Trial Details